These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25756395)

  • 1. The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial.
    Arnold DT; Hooper CE; Morley A; White P; Lyburn ID; Searle J; Darby M; Hall T; Hall D; Rahman NM; De Winton E; Clive A; Masani V; Dangoor A; Guglani S; Jankowska P; Lowndes SA; Harvey JE; Braybrooke JP; Maskell NA
    Br J Cancer; 2015 Mar; 112(7):1183-9. PubMed ID: 25756395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.
    Hooper CE; Lyburn ID; Searle J; Darby M; Hall T; Hall D; Morley A; White P; Rahman NM; De Winton E; Clive A; Masani V; Arnold DT; Dangoor A; Guglani S; Jankowska P; Lowndes SA; Harvey JE; Braybrooke JP; Maskell NA
    Br J Cancer; 2015 Mar; 112(7):1175-82. PubMed ID: 25756396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
    Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
    Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
    Eberst G; Anota A; Scherpereel A; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Léna H; Rivière F; Monnet I; Gounant V; Janicot H; Gervais R; Locher C; Charton E; Morin F; Zalcman G; Westeel V;
    Clin Cancer Res; 2019 Oct; 25(19):5759-5765. PubMed ID: 31175096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
    Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE; Fahmy ES
    Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
    de Fonseka D; Arnold DT; Stadon L; Morley A; Keenan E; Darby M; Armstrong L; Virgo P; Maskell NA
    BMC Cancer; 2018 Feb; 18(1):199. PubMed ID: 29454314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
    Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
    Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
    Mutlu H; Buyukcelik A; Karaca H; Aksahin A; Berk V; Aslan T; Erden A; Akca Z; Ozkan M
    Asian Pac J Cancer Prev; 2013; 14(6):3887-9. PubMed ID: 23886202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
    J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
    Krug LM; Wozniak AJ; Kindler HL; Feld R; Koczywas M; Morero JL; Rodriguez CP; Ross HJ; Bauman JE; Orlov SV; Ruckdeschel JC; Mita AC; Fein L; He X; Hall R; Kawabe T; Sharma S
    Lung Cancer; 2014 Sep; 85(3):429-34. PubMed ID: 25047675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
    Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
    Berardi R; Caramanti M; Fiordoliva I; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Castagnani M; Rovinelli F; Onofri A; Cascinu S
    Support Care Cancer; 2015 Mar; 23(3):621-6. PubMed ID: 25142706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
    Nakano M; Kusaba H; Makiyama A; Ariyama H; Arita S; Oda H; Esaki T; Takayoshi K; Uchino K; Tamura S; Kumagai H; Iwama E; Shirakawa T; Mitsugi K; Takaishi S; Akashi K; Baba E
    Anticancer Res; 2014 Jan; 34(1):215-20. PubMed ID: 24403465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
    Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
    J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
    Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Christoph DC; Asuncion BR; Mascaux C; Tran C; Lu X; Wynes MW; Gauler TC; Wohlschlaeger J; Theegarten D; Neumann V; Hepp R; Welter S; Stamatis G; Tannapfel A; Schuler M; Eberhardt WE; Hirsch FR
    J Thorac Oncol; 2012 Sep; 7(9):1440-8. PubMed ID: 22895141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma.
    Takeda T; Itano H; Fukita S; Saitoh M; Takeda S
    Intern Med; 2014; 53(20):2347-51. PubMed ID: 25318801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant mesothelioma, hypoalbuminaemia and the effect of carboplatin/pemetrexed on survival.
    Murphy S; Probert G; Anderson J; Pollock S; Taylor I; Clague H; Sridharan K
    Clin Oncol (R Coll Radiol); 2013 Dec; 25(12):713-8. PubMed ID: 24051173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.